FDA PCAC reviews 7 peptides for the 503A bulks list (BPC-157, KPV, TB-500, MOTs-C, Emideltide, Semax, Epitalon). Read our compounder's decision tree. Read our briefing →
FDA PCAC reviews 7 peptides for the 503A bulks list in July. Read →
FDA PCAC: 7 peptides under review. Read →
Catalog category
CagriSema, CJC+IPA, Wolverine Blend, GLOW Blend, custom-ratio multi-peptide formulations.
12 actives in this category · per-lot documented · pricing on request.
What buyers source Custom Blends & OEM for, which buyer types order it, and the documentation that ships with each lot.
Sourced for
Buyer fit
Documentation that ships
Procurement note: Ratio target, the analytical method to verify it, stability protocol, and packaging are defined in the OEM brief before the first commercial run.
Custom Blends & OEM actives
GH-axis blend (CJC-1295 no DAC + Ipamorelin)
GH-axis blend (Tesamorelin + Ipamorelin), 15 mg total
Cagrilintide + Semaglutide combination
Gonadotropin glycoprotein hormone · heavily regulated
FSH / LH-active gonadotropin · heavily regulated
Recombinant human growth hormone · heavily regulated biological
0.9% benzyl-alcohol bacteriostatic water
0.9% isotonic sodium-chloride reconstitution diluent
Preservative-free sterile water reconstitution diluent
Acidification solvent · process auxiliary
Skin-radiance multi-peptide research blend
Recovery & cellular-wellness multi-peptide blend
Sold as a multi-peptide active for research and for OEM-formulated finished products under the receiving brand's regulatory framework. Blend composition, finished-product safety, labeling claims, and notification responsibilities remain with the brand owner. Component-level analytical data is supplied for every batch.
First response under 12 hours · Catalog · Sample COA · MOQ · Lead time. Our regulatory and sales teams review every inquiry before pricing — license verification on every request.
